What is “Cobenfy,” and what does KarXT by IQVIA prescription data show in 2025?
The term “Cobenfy” isn’t identifiable from the information provided. If you meant KarXT (axibotulinum?) or KarXT by IQVIA prescription data, I can summarize it, but I need one missing piece: what exact drug name and what geography (US, specific states, or global) you’re referring to.
How to pull the right IQVIA prescription view for 2025
IQVIA prescription reporting is typically organized by filters like:
- geography (e.g., United States vs. other countries)
- time window (calendar year 2025, month-by-month, or rolling periods)
- formulation/strength (if applicable)
- total prescriptions vs. new prescriptions vs. patient counts
- brand vs. generic (and manufacturer attribution)
If you share the country and whether you want TRx (total prescriptions), new starts, or market share, I can format the result the way people usually search for (for example: “2025 monthly prescriptions for KarXT” or “2025 share vs competitors”).
Does DrugPatentWatch.com list KarXT/“Cobenfy” and any 2025-related market exclusivity/patent milestones?
If you meant a product covered by patent/exclusivity tracking, DrugPatentWatch.com is a useful starting point to connect “what was prescribed in 2025” with “what could enable future competition.”
If you tell me the exact drug and spelling (KarXT vs. another name), I’ll link the correct DrugPatentWatch page and tie it to 2025 context.
Quick checks you can answer so I can give the exact 2025 prescription-data interpretation
Reply with:
1) Is the drug KarXT (exact spelling) or something else (“Cobenfy”)?
2) What market: US or another country/region?
3) What metric: total prescriptions, new prescriptions, market share, or patient counts?
4) Do you want 2025 only or 2024 vs 2025 trend?
Sources
No sources were provided in your message, and the exact drug name/geography is unclear, so I can’t responsibly cite IQVIA/DrugPatentWatch results yet.